Top Suppliers:I want be here
Related CAS#:
58-60-6 26113-03-1
53-79-2 136680-68-7
206194-18-5 58-58-2
1158522-08-7 940364-43-2
134104-43-1 131615-57-1
6906-52-1 930439-75-1
1018584-77-4 1375289-11-4
849349-65-1 127437-46-1

58-60-6

58-60-6 structure
58-60-6 structure
  • Name: Stylomycin aminonucleoside
  • Chemical Name: 3'-amino-3'-deoxy-N6,N6-dimethyladenosine
  • CAS Number: 58-60-6
  • Molecular Formula: C12H18N6O3
  • Molecular Weight: 294.310
  • Catalog: API Antibiotics Other antibiotics
  • Create Date: 2018-06-02 08:00:00
  • Modify Date: 2024-01-01 17:38:17
  • Puromycin aminonucleoside is the aminonucleoside portion of the antibiotic puromycin, and a puromycin analog which does not inhibit protein synthesis or induce apoptosis.
Name 3'-amino-3'-deoxy-N6,N6-dimethyladenosine
Synonyms 3'-amino-3'-deoxy-N(6),N(6)-dimethyladenosine
EINECS 200-388-3
MFCD00063462
9-(3-Amino-3-deoxy-β-D-ribofuranosyl)-N,N-dimethyl-9H-purin-6-amine
Adenosine, 3'-amino-3'-deoxy-N,N-dimethyl-
3'-Amino-3'-deoxy-N,N-dimethyladenosine
PUROMYCIN AMINONUCLEOSIDE
Description Puromycin aminonucleoside is the aminonucleoside portion of the antibiotic puromycin, and a puromycin analog which does not inhibit protein synthesis or induce apoptosis.
Related Catalog
In Vitro Puromycin aminonucleoside (30 μg/mL) markedly increases p53 protein levels in podocytes. Puromycin aminonucleoside-induced podocyte apoptosis is p53 dependent and supports the notion that dexamethasone exerts an antiapoptotic effect on cells that are exposed to Puromycin aminonucleoside through the downregulation of p53. Puromycin aminonucleoside induces podocyte apoptosis in a time-dependent manner[1]. The IC50 values for PMAT-expressing and vector-transfected cells are 48.9 and 122.1 μM, respectively, suggesting expression of PMAT-enhanced cell sensitivity to Puromycin aminonucleoside. Puromycin aminonucleoside (250 μM) is toxic to both PMAT-expressing and vector-transfected cells. Puromycin aminonucleoside uptake in PMAT-expressing cells is fourfold higher at pH 6.6 than that at pH 7.4[2].
In Vivo The number of podocytes per glomerulus is 95.5±17.6 in the control rats, 90.7 on Day 4 in Puromycin aminonucleoside (8 mg/100 g, i.v.)-treated nephrosis rats. The amount of nephrin per glomerulus in control rats is 1.02±0.11 fmol and those in Puromycin aminonucleoside nephrosis rats are reduced to 0.46±0.06 fmol and 0.35±0.04 fmol on Day 4 and Day 7. The nephrin amount per podocyte is significantly decreased association with the development of proteinuria in Puromycin aminonucleoside nephrosis rats[3]. Rats given Puromycin aminonucleoside (100 mg/kg, s.c.) gain less weight and their serum creatinine levels are higher than the control rats, indicating imPuromycin aminonucleosideired renal function[4].
Cell Assay Cells are seeded in MEM with 10% FBS on 96-well plates at a density of 5,000 cells/well. After appr 48-h incubation (appr 40-50% confluence), cells are changed to fresh growth medium containing Puromycin aminonucleoside at various concentrations. For the protection experiment, cells are incubated in medium containing 250 μM Puromycin aminonucleoside with or without the PMAT inhibitor decynium-22 (2 μM). After a total of 72-h incubation in a 95% O2 incubator at 37°C, cells are washed and the plates. The IC50 values are determined by fitting the cell growth data to the following model using nonlinear regression (WinNonLin version 3.2): S=Smax − [Smax − S0] × [Cγ/(Cγ + IC50γ)], where S is the cell survival expressed as percentage of the optical density to untreated control cells, Smax is the maximal cell survival, S0 is the lowest residual cell survival at the high drug concentration, C is Puromycin aminonucleoside concentration, γ is the Hill coefficient, and IC50 is the Puromycin aminonucleoside concentration leading to half-maximal cell survival. Five to six determinations are carried out within each experiment, and four independent experiments are performed.
Animal Admin Male F344 rats at 11 weeks of age are purchased from JaPuromycin aminonucleoside SLC. Normal rats and a Puromycin aminonucleoside nephrosis model are used in the present study. Puromycin aminonucleoside nephrosis is induced in rats by a single intravenous injection of Puromycin aminonucleoside at a dose of 8 mg/100 g body weight in saline. Control animals receive an identical volume of saline. Nephrotic rats (n=6 per group) are studied at Days 4 and 7 after the Puromycin aminonucleoside injection.
References

[1]. Wada T, et al. Dexamethasone prevents podocyte apoptosis induced by puromycin aminonucleoside: role of p53 and Bcl-2-related family proteins. J Am Soc Nephrol. 2005 Sep;16(9):2615-25.

[2]. Xia L, et al. Podocyte-specific expression of organic cation transporter PMAT: implication in puromycin aminonucleosidenephrotoxicity. Am J Physiol Renal Physiol. 2009 Jun;296(6):F1307-13.

[3]. Kawakami H, et al. Dynamics of absolute amount of nephrin in a single podocyte in puromycin aminonucleoside nephrosis rats calculated by quantitative glomerular proteomics approach with selected reaction monitoring mode. Nephrol Dial Transplant. 2012 Apr;

[4]. Nosaka K, et al. An adenosine deaminase inhibitor prevents puromycin aminonucleoside nephrotoxicity. Free Radic Biol Med 1997 ;22 (4): 597-605.
Density 1.7±0.1 g/cm3
Boiling Point 595.6±60.0 °C at 760 mmHg
Melting Point 235℃ (Decomposition)
Molecular Formula C12H18N6O3
Molecular Weight 294.310
Flash Point 314.0±32.9 °C
Exact Mass 294.144043
PSA 122.55000
LogP 0.02
Vapour Pressure 0.0±1.8 mmHg at 25°C
Index of Refraction 1.776
Water Solubility H2O: 50 mg/mL, clear, slightly yellow | Soluble in water at 50mg/ml. May require heating

CHEMICAL IDENTIFICATION

RTECS NUMBER :
AU7337000
CHEMICAL NAME :
Adenosine, 3'-amino-3'-deoxy-N,N-dimethyl-
CAS REGISTRY NUMBER :
58-60-6
BEILSTEIN REFERENCE NO. :
0093902
LAST UPDATED :
199709
DATA ITEMS CITED :
8
MOLECULAR FORMULA :
C12-H18-N6-O3
MOLECULAR WEIGHT :
294.36
WISWESSER LINE NOTATION :
T56 BN DN FN HNJ IN1&1 D- BT5OTJ CQ DZ E1Q

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
105 ug/kg
SEX/DURATION :
female 5-11 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - abortion
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
45 mg/kg
SEX/DURATION :
female 8-10 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - urogenital system
TYPE OF TEST :
DNA inhibition

MUTATION DATA

TEST SYSTEM :
Rodent - mouse
DOSE/DURATION :
83 mg/kg
REFERENCE :
JCLBA3 Journal of Cell Biology. (Rockefeller Univ. Press, 1230 York Ave., New York, NY 10003) V.12- 1962- Volume(issue)/page/year: 30,13,1966
Symbol GHS08
GHS08
Signal Word Warning
Hazard Statements H373
Target Organs Kidney
Personal Protective Equipment Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter
Hazard Codes Xi
Risk Phrases 48/22
RIDADR NONH for all modes of transport
WGK Germany 3
RTECS AU7337000

Chemsrc provides CAS#:58-60-6 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 58-60-6 | Chemsrc address: https://www.chemsrc.com/en/baike/402767.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved